Can I Refuse Immunotherapy — What Happens If You Decline

Yes. Declining immunotherapy is a legitimate medical decision, not a failure of hope or willpower. Given the real cost, the months of repeat visits, and — for many cancers — genuinely uncertain benefit, choosing not to proceed is a reasonable and common choice that your oncology team should respect and support, not talk you out of.

This page assumes immunotherapy has already been offered to you. Most cancer patients are not candidates for immunotherapy in the first place — eligibility depends on cancer type and biomarker testing, confirmed by your oncology team before the question of accepting or declining even arises.

Cost is the reason named most often, and it is a legitimate one. Immunotherapy is typically given as repeat cycles over several months, and even with insurance or scheme support, the per-cycle and testing costs add up to a substantial commitment — one some families cannot sustain without real hardship elsewhere. Weighing that cost against an uncertain benefit is not a lack of hope; it is due diligence, and indicative cost figures for your specific situation are worth getting in writing from your oncology team before deciding either way.

For patients in advanced or palliative-stage disease, the calculation is different again. When the realistic goal is a modest chance of a longer or better-controlled remission rather than a cure, some patients and families reasonably prioritise quality of life, time at home, and freedom from repeat hospital visits over an additional treatment whose response rates, for many cancers, apply to only a proportion of patients. Response rates can be discussed as ranges cited by bodies like NCCN or ASCO for your specific cancer type — never assume a number you've read elsewhere applies to your own case without checking with your oncologist.

No — and any source that implies otherwise is oversimplifying. Immunotherapy attracts a lot of hopeful language, and it is genuinely reasonable to feel torn between that hope and the fear of chasing a false one. Both continuing and declining can be the right decision for different families, because the "right" choice is not graded against a universal standard — it is measured against your own goals, finances, and what your specific cancer type and biomarker results realistically predict.

What matters is that the decision is informed: that you know the realistic, cancer-specific response range, the actual cost commitment, and what continues either way. A decision made with that information, in either direction, is a good decision — regardless of which way it goes.

Declining does not end your relationship with your oncology team or your access to other care. Your oncologist documents the decision, has a conversation to confirm you understand the expected benefit and the alternatives, and then continues to offer whatever other treatment, monitoring or supportive care fits your situation — the same as for any patient.

You will not be asked to leave the hospital or clinic, and follow-up appointments, scans and symptom management continue as clinically appropriate. Many oncology teams treat this as an ongoing conversation rather than a single, irreversible decision — you can raise it again at your next review if your circumstances or your thinking changes.

Often, yes — though not in every situation, so this is worth asking your oncologist directly rather than assuming either way. If your cancer type, stage and biomarker results still make you eligible when you reconsider, and your overall fitness for treatment hasn't changed significantly, restarting the conversation is usually possible.

What can close the window is disease progression, a decline in overall fitness, or in some cases a change in what is appropriate for your specific stage by the time you reconsider. If you are declining for now but want to keep the door open, ask your oncologist what specifically would need to stay the same, and whether a shorter review period — say, at your next scan — makes more sense than treating this as a one-time, final decision.

• If part of your hesitation is about whether a good result is even possible, What Is a Durable Response, and Could It Happen to Me? explains what a long-lasting response actually means, without overselling it.
• If your case involves surgery and immunotherapy is being suggested afterward, Immunotherapy After Surgery: Why It Is Given When the Tumour Is Gone explains that specific reasoning.
• If discomfort during treatment is part of what's weighing on your decision, Is Immunotherapy Painful? What the Treatment Actually Involves sets realistic expectations.
• For the full picture of immunotherapy at CION — how it's delivered, monitored and managed — see our immunotherapy hub.

Still weighing this for your own diagnosis? Get a free second opinion and a medical oncologist will walk through it with you, whichever way you're leaning.